|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
Different studies showed that acetyl L-Carnitine (LC) positively affects the development and maturation of T lymphocytes, involved in the immune response to viral agents. It also contributes to the inhibition of ROS production and to the remodulation of the cytokine network typical of the systemic inflammatory syndrome. Given the potential protective effects of LC, it is suggested as a supportive and therapeutic option in patients with coronavirus infection. Given this background, in the light of the current COVID-19 emergency, it is the intention of the investigators to conduct a prospective, randomized, open-label, controlled study in the cohort of hospitalized patients with covid-19 pneumonia, administering 2 gr of LC orally in addition to the standard of care therapy (SOC). The investigators hypothesize that the use of LC will be associated with an earlier improvement of clinical and biohumoral parameters after 14 days of LC treatment when compared to the group of patients provided with standard care.
Description: Change of hospital mortalityMeasure: In-hospital mortality Time: 72 hours
Description: Reduction of CRP levels > 50% in comparison with CRP levels at the admission, within 72 hours after the administrationMeasure: C reactive protein (CRP) levels Time: 72 hours
Description: Reduction of IL-6 levels > 50% in comparison with IL-6 at the admission, within 72 hours after the administrationMeasure: IL-6 levels Time: 72 hours
Description: Reduction of D-dimer levels > 50% in comparison with D-dimer at the admission, within 72 hours after the administrationMeasure: D-dimer levels Time: 72 hours
Description: Length of hospital stayMeasure: Hospital stay Time: up to 24 weeks
Description: Time length of negativization of PCR molecular swabMeasure: Duration of positive PCR swab Time: 5 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports